These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17580530)

  • 1. [Farmacovigilance: the way towards a safer drug use].
    Dobrić S
    Vojnosanit Pregl; 2007 Apr; 64(4):229-30. PubMed ID: 17580530
    [No Abstract]   [Full Text] [Related]  

  • 2. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two UK Government proposals bearing on drug safety.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1997 Mar; 16(1):1-7. PubMed ID: 9192053
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug makers' adverse event reports are often incomplete, US report finds.
    McCarthy M
    BMJ; 2015 Feb; 350():h651. PubMed ID: 25652561
    [No Abstract]   [Full Text] [Related]  

  • 6. [Drug safety: from development to clinical use].
    Ovchinnikova EA; Gerasimov VB
    Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Methods for drug safety monitoring: yesterday, today, tomorrow].
    Nazimkin KE; Ovchinnikova EA; Zhuravleva MV
    Antibiot Khimioter; 2007; 52(7-8):41-52. PubMed ID: 18986024
    [No Abstract]   [Full Text] [Related]  

  • 9. EUROmediCAT: Safety of Medication Use in Pregnancy.
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24 Suppl 2():1-2. PubMed ID: 26395592
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety Meta-Analysis: A Call for Appropriate Use of Disproportionality Measures From Spontaneous Reporting Systems.
    Raschi E; Salvo F; Poluzzi E; De Ponti F
    J Am Coll Cardiol; 2016 May; 67(18):2193. PubMed ID: 27151356
    [No Abstract]   [Full Text] [Related]  

  • 11. Sequential surveillance for drug safety in a regulatory environment.
    Martin D; Gagne JJ; Gruber S; Izem R; Nelson JC; Nguyen MD; Ouellet-Hellstrom R; Schneeweiss S; Toh S; Walker AM
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):707-712. PubMed ID: 29504168
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug-related risks.
    Klotz U
    Eur J Clin Pharmacol; 2007 Nov; 63(11):983-4. PubMed ID: 17882407
    [No Abstract]   [Full Text] [Related]  

  • 13. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.
    Montastruc JL; Sommet A; Lacroix I; Olivier P; Durrieu G; Damase-Michel C; Lapeyre-Mestre M; Bagheri H
    Joint Bone Spine; 2006 Dec; 73(6):629-32. PubMed ID: 17110152
    [No Abstract]   [Full Text] [Related]  

  • 15. [Study of post marketing safety reevaluation of shenqi fuzheng injection].
    Ai QH; Li YY; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3633-6. PubMed ID: 25532410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of adverse treatment effects in controlled trials.
    Lièvre M
    Joint Bone Spine; 2006 Dec; 73(6):624-6. PubMed ID: 17113807
    [No Abstract]   [Full Text] [Related]  

  • 17. Poisons centres and the reporting of adverse drug events: the case for further development.
    Volans GN; Karalliedde L; Wiseman HM
    Drug Saf; 2007; 30(3):191-4. PubMed ID: 17343427
    [No Abstract]   [Full Text] [Related]  

  • 18. A clinicians' guide to adverse drug reactions.
    Ranganathan SS; Fernandopulle R
    Ceylon Med J; 2007 Jun; 52(2):41-4. PubMed ID: 17691557
    [No Abstract]   [Full Text] [Related]  

  • 19. Reporting of adverse drug events: a key to postmarketing drug safety.
    Rheinstein PH
    Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
    [No Abstract]   [Full Text] [Related]  

  • 20. Outliers and patients with adverse drug reactions.
    Edwards IR
    Drug Saf; 2009; 32(8):623-4. PubMed ID: 19591527
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.